[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447105":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":64,"collaborators":66,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":10,"studyType":88,"phases":10,"briefSummary":89,"conditions":90,"keywords":10,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Origin Sciences","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-small cell lung cancer",null,"A cohort of patients with known NSCLC who are assessed.",[13],"Diagnostic Test: Oricol Test",{"label":15,"type":10,"description":16,"interventionNames":17},"Pancreatic cancer","A cohort of patients with known pancreatic adenocarcinoma who are assessed.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Urothelial cancers","A cohort of patients with known uroepithelial cancers who are assessed.",[13],{"label":23,"type":10,"description":24,"interventionNames":10},"Colorectal cacncers","A cohort of patients with known colorectal cancers have been added to the study following methodology change in analysis techniques.",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"DIAGNOSTIC_TEST","Oricol Test","Assessment of rectal mucus for material from aero-digestive cancers.",[9,15,19],[32],{"name":33,"affiliation":34,"role":35},"Mr F McDermott, FRCS","Chief Investigator","STUDY_DIRECTOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Ian Daniels, FRCS","CONTACT","01223 750490","Ian.Daniels@originsciences.com",{"name":43,"role":39,"phone":44,"phoneExt":10,"email":45},"Hugo Lywood","01223750490","hugo.lywood@originsciences.com",[47],{"facility":48,"status":49,"city":50,"state":10,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Royal Devon & Exeter NHS Foundation Trust","RECRUITING","Exeter","EX2 4UG","United Kingdom","UK",{"type":55,"coordinates":56},"Point",[57,58],-3.52751,50.7236,{"lat":58,"lon":57},[61],{"name":62,"role":39,"phone":63,"phoneExt":10,"email":41},"Ian Daniels","+447920517187",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[67,70,72],{"name":68,"class":69},"Royal Devon and Exeter NHS Foundation Trust","OTHER",{"name":71,"class":69},"Norfolk and Norwich University Hospitals NHS Foundation Trust",{"name":73,"class":69},"The Leeds Teaching Hospitals NHS Trust","100447105","feasibility-study-to-investigate-rectal-mucus-in-aero-digestive-tract-cancer-100447105",false,"NCT05102110","Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.","Feasibility Study to Investigate the Genomic and Epigenetic Changes in Rectal Mucus in Non-Colorectal Cancers of the Aero-Digestive Tract (ORI-EGI-03).","ORI-EGI-03","Inclusion Criteria:\n\nAged 18 years or over Be able to give voluntary, written informed consent to participate in the study\n\nExclusion Criteria:\n\nParticipants with symptoms that would make proctoscopic examination inappropriate, including acute anal fissure, symptomatic thrombosed haemorrhoids or obstructing anorectal lesions as determined by rectal examination Participants with a previous history of cancer Participants who have received previously radiotherapy, chemotherapy or immunotherapy for a malignancy.","ALL","18 Years","99 Years",{"count":86,"type":87},450,"ESTIMATED","OBSERVATIONAL","The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device.\n\nThe primary objective of the study is to assess whether significant changes in DNA mutation and methylation associated with Non-colorectal cancers of the Aero-digestive Tract (NCRCADT) can be detected in rectal mucus as shed cells and cell-free DNA (cfDNA) pass through the gut and theoretically can be collected from rectal mucus.\n\nSecondary objectives will assess the participant acceptability of the OriCol™ Sampling Device for Pancreatic Ductal Adenocarcinoma, Non-Small Cell Cancer of the Lung, Colorectal Cancer and Urological Cancer controls as well as contributing to a genomic library collating information about rectal mucus.",[91,92,93,94],"Non Small Cell Lung Cancer","Pancreatic Cancer","Bladder Cancer","Colorectal Cancer","2026-03-12",{"date":97,"type":98},"2026-03-16","ACTUAL",{"date":100,"type":98},"2021-12-01",{"date":102,"type":87},"2027-12-01",{"name":5,"class":6},1]